2025-09-25 - Analysis Report
Okay, here's a comprehensive analysis of Natera (NTRA) based on the provided data. The report is structured to provide a clear picture of the company's performance, technical indicators, recent news, and analyst opinions, concluding with an overall assessment.

```markdown
## Natera Inc (NTRA) Analysis

**Company Overview:** Natera Inc. is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 44.86%
*   **VOO Cumulative Return:** 70.68%
*   **Absolute Divergence:** -25.82% (NTRA underperformed VOO by this amount)
*   **Relative Divergence:** 16.6 (Indicates NTRA's divergence from VOO is in the lower range of its historical divergence)

**Analysis:** NTRA has significantly underperformed the S&P 500 over the period. The relative divergence suggests that this underperformance is not unusual for NTRA historically.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 2.0%   | 67.9%  | -20.0%  | 0.1    | 1.2    |
| 2016-2018  | 30.0%  | 78.6%  | 12.0%   | 0.1    | 1.9    |
| 2017-2019  | 27.0%  | 78.6%  | 1.0%    | 0.6    | 4.6    |
| 2018-2020  | 97.0%  | 95.0%  | 85.0%   | 0.5    | 13.7   |
| 2019-2021  | 34.0%  | 95.0%  | 5.0%    | 0.5    | 12.8   |
| 2020-2022  | -62.0% | 95.0%  | -57.0%  | 0.3    | 5.5    |
| 2021-2023  | -116.0%| 98.3%  | -127.0% | -0.3   | 8.6    |
| 2022-2024  | -2.0%  | 98.3%  | -26.0%  | 0.1    | 21.7   |
| 2023-2025  | 67.0%  | 98.3%  | 28.0%   | 0.3    | 23.0   |

**Analysis:**

*   **CAGR & MDD:** NTRA exhibits high volatility, with significant swings in both positive and negative returns. The high Maximum Drawdown (MDD) values indicate substantial risk.
*   **Alpha:** Alpha is inconsistent, ranging from significantly negative to highly positive, suggesting performance highly dependent on the specific period. Recent years show negative alpha, indicating underperformance relative to its risk-adjusted expected return.
*   **Beta:** Beta values are generally low, indicating lower sensitivity to market movements compared to the S&P 500, although it varies over time, even turning negative in one period.
*   **Market Cap:** The company's market capitalization has fluctuated, showing growth in some periods and decline in others.

### 2. Recent Stock Price Trends

*   **Current Price:** 167.68
*   **Last Market Data:** Price: 167.755, Previous Close: 172.83, Change: -2.94
*   **5-Day Moving Average:** 176.654
*   **20-Day Moving Average:** 171.1256
*   **60-Day Moving Average:** 157.9014

**Analysis:**

*   The current price is below the 5-day and 20-day moving averages, suggesting a short-term downtrend. However, it's above the 60-day moving average, indicating a potentially stronger longer-term trend.
*   The recent price change indicates a negative movement, confirming the short-term downtrend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 50.14 (Neutral)
*   **PPO:** -0.26 (Below 0, suggesting a potential downtrend but close to zero)
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.41)
*   **Recent (20-day) Relative Divergence Change:** 2.6 (+): Short-term increase
*   **Expected Return:** 78.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates medium risk.
*   The RSI is neutral, suggesting neither overbought nor oversold conditions.
*   The PPO is slightly negative but close to zero, indicating a possible weakening trend.
*   The hybrid signal suggests a cautious approach, recommending partial buying with available cash.
*   The increase in relative divergence could indicate some short-term positive momentum.
*   The high expected return suggests significant potential upside over the long term.

### 4. Recent News & Significant Events

*   **[2025-09-22] Humana initiated, Paycom upgraded:** (The Fly) - This article might provide a broader context of market sentiment towards healthcare-related companies.
*   **[2025-09-22] Natera Insider Sold Shares Worth $9,016,668:** (MT Newswires) - Insider selling can often be perceived negatively by the market.
*   **[2025-09-12] Why Natera (NTRA) Stock Is Trading Lower Today:** (StockStory) - Important for understanding immediate factors impacting the stock price.
*   **[2025-09-11] Discover September 2025's Stocks That May Be Trading Below Estimated Value:** (Simply Wall St.) - Suggests Natera might be undervalued according to some metrics.
*   **[2025-09-10] Why Natera (NTRA) Shares Are Falling Today:** (StockStory) - Similar to the 9/12 article, explains recent price decline.
*   **[2025-09-10] 3 Reasons We’re Fans of Natera (NTRA):** (StockStory) - Provides a counterpoint to the negative news, highlighting potential positives.

**Analysis:** Recent news presents a mixed picture. Insider selling and articles explaining stock declines are concerning. However, articles suggesting undervaluation and positive reasons for liking the stock offer some optimism.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.52 (~Buy)
*   **Opinions:** 21
*   **Target Price (avg/high/low):** 197.33 / 268.00 / 37.00
*   **Recent Rating Changes:** (No specific changes provided)

**Analysis:** The analyst consensus is strongly positive, with a "Buy" rating and a target price significantly above the current price. However, the wide range in target prices indicates uncertainty.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2024-08-09 | -0.3  | 0.41 B$    |
| 2025-08-08 | -0.3  | 0.41 B$    |

**Analysis:**

*   Natera is currently unprofitable, with consistent negative EPS.
*   Revenue has generally been increasing, but plateaued recently.
*   The latest EPS (-0.74) is significantly worse than previous quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.55B  | 63.41%       |
| 2025-03-31   | $0.50B  | 63.12%       |
| 2024-12-31   | $0.48B  | 62.94%       |
| 2024-09-30   | $0.44B  | 61.79%       |
| 2024-06-30   | $0.41B  | 58.83%       |

**Capital and Profitability:**

| Quarter      | Equity  | ROE     |
|--------------|---------|---------|
| 2025-06-30   | $1.25B  | -8.10%  |
| 2025-03-31   | $1.24B  | -5.40%  |
| 2024-12-31   | $1.20B  | -4.50%  |
| 2024-09-30   | $0.88B  | -3.60%  |
| 2024-06-30   | $0.84B  | -4.48%  |

**Analysis:**

*   **Revenue:** Revenue shows a positive trend over the past few quarters, indicating growth in the company's sales.
*   **Profit Margin:** The profit margin is high, indicating strong pricing power and efficient cost management in its operations, but it is important to note that these are gross profit margins.
*   **Equity:** Equity has been increasing, suggesting a strengthening financial position.
*   **ROE:** The Return on Equity (ROE) is negative, consistent with the negative EPS, indicating the company is not generating profits relative to its equity.  The increasing negative ROE suggests that profitability is worsening relative to equity.

### 7. Overall Assessment

Natera (NTRA) presents a mixed investment picture.

**Positives:**

*   **High Growth Potential:** The company operates in a growing sector (genetic testing) and has a high long-term expected return.
*   **Strong Revenue Growth:** Revenue is increasing, suggesting growing market acceptance of its products.
*   **High Profit Margins:** Strong pricing power is indicated by high gross profit margins.
*   **Analyst Support:** Strong "Buy" consensus from analysts.
*   **Potential Undervaluation:** Some sources suggest the stock might be trading below its estimated value.

**Negatives:**

*   **Unprofitable:** The company is currently unprofitable, with negative EPS and ROE. The latest EPS is concerning.
*   **High Volatility:** NTRA exhibits high price volatility.
*   **Underperformance:** Has underperformed the S&P 500 significantly.
*   **Insider Selling:** Recent insider selling could indicate a lack of confidence from within the company.
*   **Recent Downtrend:** The stock is currently in a short-term downtrend.
*   **High Risk:** The MDD (Maximum Drawdown) indicates significant risk.

**Conclusion:**

Investing in NTRA is speculative. While there is potential for high returns, there are also significant risks.  A potential investor needs to be comfortable with high volatility and the company's current lack of profitability. The recent negative news and the short-term downtrend warrant caution. The analyst consensus and long-term growth potential might appeal to aggressive investors, but a careful risk assessment is crucial.
```

**Key takeaways:**

*   **Risk Tolerance:** NTRA is suitable for investors with a high risk tolerance due to its volatility and lack of current profitability.
*   **Due Diligence:** Further investigation into the reasons behind the insider selling and the recent EPS decline is warranted.
*   **Long-Term Perspective:** The potential upside relies on the company achieving profitability and realizing its long-term growth potential.
